Abstract
Objective: Japan Society of Ningen Dock (JSND) created a database of subjects receiving annual health examinations at 21 institutions nationwide. Using this database, we evaluated the efficacy of current treatment for patients with dyslipidemia, hypertension and diabetes mellitus based on the recommendations of the Japan Atherosclerosis Society (JAS), the Japanese Society of Hypertension (JSH) and the Japan Diabetes Society (JDS), respectively.
Results: 1. Status of dyslipidemia treatment (n=17,694): According to the JAS 2007 guidelines, the achievement rates of serum lipid management goals were as follows: LDL-C, 72.3%; HDL-C, 94.6%; and TG, 69.7%. 2. Status of hypertension treatment (n=31,754): According to the JSH 2009 guidelines, the target office blood pressure was achieved by 45.2% of all subjects. When 140/90 mmHg were used as the hypertension criteria for conventional blood pressure measurements, the achievement rate was 69.8%. 3. Status of diabetes treatment (n=7,020): According to the JDS 2013 guidelines, 44.8% of the patients fell into the good glycemic control category with a HbA1c level < 7.0%. 4. Lifestyle and lipids, blood pressure and glycemic control: Lifestyle habits were strongly associated with lipids, blood pressure and glycemic control in patients with dyslipidemia, hypertension and diabetes treatment.
Conclusions: Our results indicate that management of lifestyle-related diseases in Japanese patients receiving treatment for dyslipidemia, hypertension and diabetes is insufficient. Stricter management including lifestyle modification is necessary for reducing rates of complications.
